Eton Pharmaceuticals (ETON) Scheduled to Post Quarterly Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The business had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $10.00 million. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Up 1.3 %

ETON opened at $8.78 on Monday. The business has a fifty day moving average of $6.86 and a 200 day moving average of $4.77. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $9.12. The stock has a market cap of $226.84 million, a P/E ratio of -33.77 and a beta of 1.25.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ETON shares. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th. HC Wainwright upped their target price on Eton Pharmaceuticals from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, October 4th.

Insiders Place Their Bets

In other news, major shareholder Opaleye Management Inc. bought 57,500 shares of the stock in a transaction on Tuesday, September 10th. The stock was acquired at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the acquisition, the insider now owns 2,660,000 shares of the company’s stock, valued at $12,369,000. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders bought 85,600 shares of company stock worth $462,674. 14.89% of the stock is currently owned by company insiders.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.